Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Leora Horn

13 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCTHO1602

    09/23/2016

    An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations

    Treatment

    VICCTHO1603

    09/15/2016

    A Phase 2 Study of LY2606368 in Patients with Extensive Stage Disease Small Cell Lung Cancer

    Treatment

    VICCTHO1614

    08/05/2016

    A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer

    Treatment

    VICCTHO15129

    06/07/2016

    XALT3: Phase 3 Randomized Study Comparing X-396 to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients

    Treatment

    VICCTHO1625

    06/01/2016

    An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as First Line-Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)

    Treatment

    ECOGTHOS1403

    04/26/2016

    A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) (BI 1200.124)

    Treatment

    VICCTHO1595

    03/25/2016

    An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinum-based First Line Chemotherapy

    Treatment

    VICCTHO1573

    02/01/2016

    An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

    Treatment

    VICCTHO1519

    10/07/2015

    A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti−PDL1 Antibody) Compared with Cisplatin or Carboplatin+Pemetrexed for PD-L1−Selected Chemotherapy Naive Patients with Stage Iv Non-Squamous Non−Small Cell Lung Cancer

    Treatment

    VICCTHO1510

    07/09/2015

    A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Treatment

    VICCTHO1443

    03/11/2015

    A Phase III, Randomized, Open-Label, Cross-Over, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane?) as Maintenance Treatment after Induction with Nab-Paclitaxel Plus Carboplatin in Subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC)

    Treatment

    VICCTHO1478

    11/14/2014

    A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination with Ascending Doses of Novel Therapeutics in Patients with EGFRm+ Advanced NSCLC who have progressed following therapy with an EGFR TKI (TATTON)

    Treatment

    VICCTHN1244

    07/25/2012

    Phase 1, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-396 in Patients with Advanced Solid Tumors


    Print this page for your doctor